Drug Discovery

#Drug discovery #Infectious diseases #Molecular Biology #Research

Researchers discover way to disarm potentially deadly Listeria bacteria 

University of Queensland researchers have discovered a way to block Listeria from making the proteins that allow bacteria to survive and multiply in immune cells, which can cause severe illness in pregnant women and people with compromised immune systems. The study has been published in the journal PLOS Pathogens. Read More

#News

#Drug discovery

This week in drug discovery (24-28 January) 

News round-up by DDW’s Megan Thomas for 24-28 January, 2022  From further Covid-19 developments to cancer and chronic pain studies, there is a lot to appreciate and get excited about in the drug discovery sector. DDW’s Megan Thomas has rounded up five stories that have stood out… Read More

#News

#Biopharmaceuticals #Drug discovery #R&D #Therapeutics

Sitting down with… Dr Michael Hayden, Prilenia Therapeutics

Listen to this article on the DDW Podcast: Dr Michael Hayden’s early encounters and experience with patients and families suffering from Huntington’s Disease has had a significant personal impact that shaped his career. As CEO of Prilenia Therapeutics, he tells Lu Rahman why he has dedicated his career… Read More

#Editor's Choice #Exclusive Content #News #Opinion

CRISPR gene editing
#3D modelling #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Screening

CRISPR screening in the third dimension 

Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.  While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the… Read More

#Editor's Choice #Exclusive Content #News

#Assays #Biotechnology #Drug discovery #Enzymes #TechNote

TechNote: Radioactivity assays for methyltransferase enzymes

In this free TechNote by SAMDI Tech, learn how the company’s radioactivity assays overcome key challenges in drug discovery by offering key solutions, including: Detecting low amounts of product with sensitive assays Generating data rapidly with high-throughput, 384-well capabilities Characterising potent inhibitors by benefiting from lower enzyme concentrations Learn… Read More

#News #Trending News

#Biochemistry #Drug discovery #Mass spectrometry / NMR

How ASMS offers more than seeing what sticks 

Listen to this article on the DDW Podcast: Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech, breaks down three critical components to consider to ensure a successful affinity selection mass spectrometry (ASMS) drug discovery programme.  The ability to rapidly identify small molecules that non-covalently bind to… Read More

#Editor's Choice #Exclusive Content #News

#Drug discovery #Funding #Healthcare #Investment #Life sciences #Public health

Drug discovery investors: Who’s spending? 

While the research, results and trials often take centre-stage when it comes to drug discovery and development reporting, DDW’s Megan Thomas spotlights the funding and investments which make this possible.   1. US researcher awarded $3.6 million to study antibiotic resistance  Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Drug discovery #Genomics #Life sciences #Molecular Biology

Finding the right cancer drug with high-content screening

Listen to this article on the DDW Podcast: Lassi Paavolainen, Principal Investigator at the Institute for Molecular Medicine Finland (FIMM), Vilja Pietiäinen, Adjunct Professor in Cell and Molecular Biology, and Amanda Jones, Life Science Research Strategy Leader at PerkinElmer explain how functional precision medicine using ex vivo drug testing… Read More

#Editor's Choice #News

#Drug discovery #Events #Lab automation #SLAS2022

What to expect from SLAS2022 

SLAS2022 in Boston is moving ahead as an in-person event with a hybrid component from February 5-9, 2022 at Boston Convention & Exhibition Center, which unsurprisingly has many from the drug discovery industry excited, including the DDW team, who will be stationed at Booth 1945.   DDW has teamed up… Read More

#Exclusive Content #News #Trending News

#Biology #Drug discovery #Protein chemistry / Proteomics #Therapeutics

Why the emergence of targeted protein degradation is so exciting 

Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More

#hidden

#Comment #Covid-19 #Drug discovery #Podcast

From here to there: What lies ahead for drug discovery – podcast

This is the latest episode of the free DDW podcast, “From here to there: What lies ahead for drug discovery”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas. The articles are called “The complexity of disease… Read More

#News

#Drug discovery

This week in drug discovery (17-21 January) 

News round-up by DDW’s Megan Thomas for 17-21 January, 2022  When it comes to drug discovery and development, it’s all about the research, the breakthroughs and the next step. DDW’s Megan Thomas has rounded up five stories which highlight this theme of progress.  1. Read More

#News #Trending News

#Biotechnology #Drug discovery #Therapeutics

Drug discovery movers: who’s going where? 

The new year is underway and with it comes a raft of movement within some of the industry’s key businesses. DDW’s Megan Thomas rounds up seven new additions to the sector.  Dr Charles Woler (Sygnature Discovery, UK)  Sygnature Discovery, provider of drug discovery solutions, has appointed Dr Charles Woler as Chairman. Dr Woler has… Read More

#News #Trending News

#Collaboration #Drug candidates #Drug discovery

Drug discovery collaboration tackles metabolic diseases

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes.  The collaboration  The collaboration leverages Evotec’s metabolic disease experience, as well as its kidney disease patient database,… Read More

#News

#Biotechnology #Clinical trials #Drug development #Tumours

Avacta takes step to increase the tolerability of chemotherapies  

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.  The technology  Avacta’s chemistry is used to modify chemotherapy drugs to render them inactive… Read More

#News

#AI / data analytics / healthtech / informatics #Comment #Drug discovery #SLAS2022

Comment: AI-powered drug discovery 

The Winter issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & SLAS2022 supplement ahead of SLAS2022 in Boston, US on 5-9 February. As we all look forward to the expertise at the event, DDW’s Megan Thomas outlines the highlights of the first SLAS 2021 AI-Powered Drug Discovery… Read More

#Editor's Choice #Exclusive Content #News #Opinion